Poseida Therapeutics Inc
NASDAQ:PSTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2
4.13
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Poseida Therapeutics Inc
Poseida Therapeutics Inc
Total Equity
Poseida Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Poseida Therapeutics Inc
NASDAQ:PSTX
|
Total Equity
$103.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
$6B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$18.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$7.5B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$15.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$29.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
28%
|
|
Poseida Therapeutics Inc
Glance View
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).
See Also
What is Poseida Therapeutics Inc's Total Equity?
Total Equity
103.7m
USD
Based on the financial report for Dec 31, 2023, Poseida Therapeutics Inc's Total Equity amounts to 103.7m USD.
What is Poseida Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 3Y
-27%
Over the last year, the Total Equity growth was -45%. The average annual Total Equity growth rates for Poseida Therapeutics Inc have been -27% over the past three years .
You don't have any saved screeners yet
